NCT05023655
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ARID1A
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled central nervous system (CNS) metastases requiring steroids; Patients with prior exposure to tazemetostat or other inhibitor(s) of EZH2
https://ClinicalTrials.gov/show/NCT05023655